There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on FibroGen (NASDAQ:FGEN) and Trillium Therapeutics (NASDAQ:TRIL) with bullish sentiments.
FibroGen (FGEN)
Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen today and set a price target of $74. The company’s shares opened today at $61.
Yang observed:
“We see the NDA submission in Japan as a positive development for the company demonstrating continued execution by management/partner on the global roxadustat development program. A number of data readouts are anticipated in 4Q18 for roxadustat (highlighted below), which we believe will be important catalysts for the shares.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 26.2% and a 55.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
FibroGen has an analyst consensus of Moderate Buy, with a price target consensus of $75.67.
See today’s analyst top recommended stocks >>
Trillium Therapeutics (TRIL)
Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics today. The company’s shares opened today at $5.61, close to its 52-week low of $4.80.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 11.5% and a 44.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Corvus Pharmaceuticals Inc, and Stemline Therapeutics Inc.
Trillium Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
